Evicenter
MarkdownMedical informationP&T meetings
Ficerafusp alfa (BCA101)

First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab

Last updated
135 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care

Limitations of current therapies

18 evidence topics · 22 sources

Summary: response, survival, and PD-L1 selection with first-line pembrolizumab regimens

Pembrolizumab monotherapy is approved for first-line recurrent or metastatic HNSCC with PD-L1 CPS ≥1, and pembrolizumab with platinum and fluorouracil for all first-line patients. ASCO states that “Response rates to single-agent pembrolizumab remain close to 20%, regardless of prior exposure to therapy or PD-L1 expression”. At the KEYNOTE-048 4-year follow-up, the objective response rate with pembrolizumab alone was 19.1% versus 34.9% with cetuximab-chemotherapy in the CPS ≥1 population and 16.9% versus 36.0% in the total population; with pembrolizumab-chemotherapy it was 37.2% (CPS ≥1) and 36.3% (total). Neither pembrolizumab regimen improved progression-free survival at the second interim analysis, when median progression-free survival in the CPS ≥1 subgroup was 3.2 months with pembrolizumab versus 5.0 months with cetuximab-chemotherapy. At the 4-year follow-up, median overall survival was 12.3 months with pembrolizumab (CPS ≥1) and 13.0 months with pembrolizumab-chemotherapy (total population); 5-year overall survival in the total population was 14.4% and 16.0%, and the survival curve with pembrolizumab alone reached a plateau at approximately 20%. The median duration of pembrolizumab exposure was 3.5 months with monotherapy and 5.8 months in the combination arm. In exploratory analyses that were not prespecified, median overall survival with pembrolizumab alone versus cetuximab-chemotherapy was 10.8 versus 10.1 months in the CPS 1-19 subgroup (hazard ratio 0.86, 95% CI 0.66 to 1.12), and median overall survival was 7.9 versus 11.3 months in the CPS <1 subgroup (hazard ratio 1.51, 95% CI 0.96 to 2.37).

Summary: toxicity and administration of chemotherapy-containing regimens

At the KEYNOTE-048 4-year follow-up, grade ≥3 treatment-related adverse events occurred in 17.0% of participants receiving pembrolizumab alone, 71.7% receiving pembrolizumab-chemotherapy, and 69.3% receiving cetuximab-chemotherapy. Fluorouracil requires a “continuous 4-day infusion” and is associated with “cardiovascular and gastrointestinal toxicities”. In EXTREME, fatal cardiac disorders or sudden death occurred in 3% of 219 participants treated with cetuximab plus platinum and fluorouracil. With a taxane in place of fluorouracil alongside pembrolizumab and carboplatin, grade 3 to 5 treatment-related adverse events occurred in 76 of 101 treated participants (75%). NCI states that chemotherapy has been shown to induce responses with no demonstrated increase in survival; in randomized trials, cisplatin plus fluorouracil did not improve overall survival over methotrexate, and response rates were 32% with cisplatin plus fluorouracil and 10% with methotrexate in one trial, and 27% with cisplatin plus fluorouracil and 26% with cisplatin plus paclitaxel in another.

Summary: outcomes in HPV-negative disease

Response and survival with current therapy are lower in HPV-negative than in HPV-positive disease. In Argiris et al. (2014), the objective response rate was 19% for HPV-negative versus 55% for HPV-positive tumors, and median survival was 6.7 versus 12.9 months. After progression of oropharyngeal cancer, 2-year overall survival was 27.6% for p16-negative versus 54.6% for p16-positive disease. With first-line pembrolizumab in U.S. practice, median real-world overall survival in HPV-negative versus HPV-positive disease was 9 versus 20 months on monotherapy and 7 versus 15 months with chemotherapy. ASCO states that current data “do not support changing recommendations” for anti-PD-1 therapy “with regard to the HPV status.”

Summary: options after progression and for locoregional recurrence

The FDA states that approved therapies after platinum-based chemotherapy are associated with an overall response rate of around 20% or less. On November 5, 2026, amivantamab and hyaluronidase-lpuj received accelerated approval after progression on platinum-based chemotherapy and an anti-PD-(L)1 antibody, excluding HPV-associated oropharyngeal squamous cell carcinoma, based on an overall response rate of 42% in the 102-participant primary efficacy population of OrigAMI-4, a multicenter, open-label, multi-cohort trial. Conventional salvage regimens yield response rates of 21% to 69%, median progression-free survival of 2.9 to 5.5 months, and median overall survival of 6.3 to 13.3 months, and a review states that there is “no clear standard of care choice in second-line treatment”. For locoregional recurrence after prior radiation, reirradiation with intensity-modulated radiotherapy had pooled late grade ≥3 and grade 5 toxicity rates of 26% and 3.1%, and postoperative reirradiation with chemotherapy after salvage surgery improved disease-free survival without a significant effect on overall survival.